Our Brand Division
The Watson Brand division brings diversification to our business mix through a portfolio of patented and off-patented trademarked products. This business develops, manufactures and markets its products through two core areas: our Specialty Products product line includes urology and a number of other non-promoted products, and our Nephrology product line, which is primarily marketed to nephrologists and dialysis centers, features products for the treatment of iron deficiency anemia. The Watson Brand division is integral to our Company’s long-term strategy for “balanced” growth.
Highlights
- Focused on specialty physicans (urology and nephrology)
- 25 pharmaceutical product families in the portfolio
- Generated $429 million in brand revenue during 2007
- Accounted for 17% of total 2007 annual revenue at Watson
Key Brands
| In Urology | In Nephrology |
|---|---|
|
OXYTROL® (KENTERA® in Europe)
A treatment for overactive bladder symptoms |
FERRLECIT® / INFeD®
IV iron replacement therapies for certain patients with iron deficiency anemia |
|
TRELSTAR® LA / TRELSTAR® DEPOT
A treatment for advanced prostate cancer symptoms |
R&D Pipeline
| Indication/Therapeutic Target |
 |
 |
 |
 |
 |
 |
 |
|
|---|---|---|---|---|---|---|---|---|
|
RAPAFLO TM
|
Benign-Prostatic Hyperplasia/Urology | U.S. |  |
|
|
|
|
|
| Oxybutynin Gel |
Overactive Bladder/Urology
|
U.S. | |
|
|
|
||
|
TRELSTAR®
6-month formulation |
Advanced Prostate Cancer/Urology | U.S. | |
|
|
|
||
|
URACYST®
|
Interstitial cystitis | U.S. | |
|
